(Q40016903)

16 September 2017

title

Development of pyrrolo[2,1-c][1,4]benzodiazepine beta-galactoside prodrugs for selective therapy of cancer by ADEPT and PMT. (English)

1 reference

16 September 2017

1

Ahmed Kamal

1 reference

16 September 2017

Venkatesh Tekumalla

2

1 reference

16 September 2017

Anita Krishnan

series ordinal

3

1 reference

16 September 2017

Manika Pal-Bhadra

series ordinal

4

1 reference

16 September 2017

Utpal Bhadra

series ordinal

5

1 reference

16 September 2017

publication date

1 May 2008

1 reference

16 September 2017

1 reference

16 September 2017

volume

3

1 reference

16 September 2017

issue

5

1 reference

16 September 2017

page(s)

794-802

1 reference

Antibody directed enzymes revive anti-cancer prodrugs concept

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

Tumor-activated prodrugs--a new approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Enzyme and Proton-Activated Prodrugs for a Selective Cancer Therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Prodrug strategies in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Antibody-directed enzyme prodrug therapy (ADEPT): a review

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Cloning and characterization of human liver cytosolic beta-glycosidase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Cytosolic beta-glycosidases for activation of glycoside prodrugs of daunorubicin.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Senescence-associated beta-galactosidase is lysosomal beta-galactosidase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Endogenous beta-galactosidase expression in murine pancreatic islets

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

The relevance of drug DNA sequence specificity to anti-tumour activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Design, synthesis, and evaluation of new noncross-linking pyrrolobenzodiazepine dimers with efficient DNA binding ability and potent antitumor activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

DNA binding potential and cytotoxicity of newly designed pyrrolobenzodiazepine dimers linked through a piperazine side-armed-alkane spacer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Synthesis, DNA binding, and cytotoxicity studies of pyrrolo[2,1-c][1,4]benzodiazepine-anthraquinone conjugates

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Synthesis of C8-linked pyrrolo[2,1-c][1,4]benzodiazepine-benzimidazole conjugates with remarkable DNA-binding affinity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Design and synthesis of C-8 linked pyrrolobenzodiazepine-naphthalimide hybrids as anti-tumour agents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Design and synthesis of novel pyrrolobenzodiazepine (PBD) prodrugs for ADEPT and GDEPT

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Antibody-directed enzyme prodrug therapy (ADEPT) for cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Conjugates of COL-1 monoclonal antibody and beta-D-galactosidase can specifically kill tumor cells by generation of 5-fluorouridine from the prodrug beta-D-galactosyl-5-fluorouridine

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

The role of pro-drug therapy in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Generation of an intensely potent anthracycline by a monoclonal antibody-beta-galactosidase conjugate

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

A strategy for tumor-selective chemotherapy by enzymatic liberation of seco-duocarmycin SA-derivatives from nontoxic prodrugs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Determination of lymphocyte division by flow cytometry

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200700328

7 January 2021

Identifiers

DOI

10.1002/CMDC.200700328

1 reference

16 September 2017

1 reference